5-HT1F agonists
- PMID: 38307661
- DOI: 10.1016/B978-0-12-823357-3.00032-X
5-HT1F agonists
Abstract
5-Hydroxytryptamine (HT)/serotonin receptor agonism has been a long-recognized property of triptan medications, and more recently, the study and development of medications with selective binding to the 1F receptor subtype have been explored. While the exact mechanism contributing to decreased symptoms of an acute migraine attack remains unclear, selective 5-HT1F agonists have demonstrated clinical efficacy with lasmiditan as the only approved medication from this class to date. Lasmiditan lacks vasoconstrictive properties, giving it utility in specific patient populations in whom triptans should be avoided. Availability, central nervous system (CNS) side effects, and 8-hour driving restriction may affect its clinical use.
Keywords: Lasmiditan; Migraine; Rescue therapy; Serotonin agonists; Trigeminal ganglia.
Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Similar articles
-
Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.Prog Brain Res. 2020;255:99-121. doi: 10.1016/bs.pbr.2020.05.010. Epub 2020 Jun 12. Prog Brain Res. 2020. PMID: 33008517 Review.
-
Targeted 5-HT1F Therapies for Migraine.Neurotherapeutics. 2018 Apr;15(2):291-303. doi: 10.1007/s13311-018-0615-6. Neurotherapeutics. 2018. PMID: 29488143 Free PMC article. Review.
-
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.Expert Opin Pharmacother. 2017 Sep;18(13):1409-1415. doi: 10.1080/14656566.2017.1361406. Epub 2017 Aug 10. Expert Opin Pharmacother. 2017. PMID: 28749698 Review.
-
Lasmiditan mechanism of action - review of a selective 5-HT1F agonist.J Headache Pain. 2020 Jun 10;21(1):71. doi: 10.1186/s10194-020-01132-3. J Headache Pain. 2020. PMID: 32522164 Free PMC article. Review.
-
Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.Cephalalgia. 2022 Jan;42(1):20-30. doi: 10.1177/03331024211048507. Epub 2021 Oct 13. Cephalalgia. 2022. PMID: 34644189 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources